Innovent Biologics will present nearly 10 sets of clinical data on its novel oncology molecules at the European Society of Medical Oncology (ESMO) Asia Congress 2024, held in Singapore from December 6-8, 2024.
A highlight of the presentations will be the updated Phase 1 results of IBI343, a novel TOPO1i CLDN18.2 antibody-drug conjugate (ADC), in patients with previously-treated pancreatic cancer. The data, to be presented by Jian Zhang from Fudan University Shanghai Cancer Center, will be featured in a mini oral session.
IBI343 Shows Promise in Pancreatic Cancer
IBI343 is designed with a Fc-silent antibody, a stable linker, and a potent extecan payload. According to Innovent, the dose expansion stage data demonstrated encouraging efficacy and good safety, reinforcing confidence in advancing its development for pancreatic ductal adenocarcinoma (PDAC) treatment. Pancreatic cancer remains a difficult-to-treat malignancy, and IBI343 represents a pioneering approach in exploring CLDN18.2 ADC agents for this indication.
Combination Therapies with Sintilimab
Innovent will also present data on several combination therapies involving sintilimab, an anti-PD-1 antibody. These include:
- A Phase 2 study of anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC).
- A Phase 2 study of hepatic arterial infusion chemotherapy (HAIC) combined with donafenib and sintilimab as first-line treatment for unresectable intrahepatic cholangiocarcinoma (CHANCE 2203).
- A Phase 2 study of FOLFOX-HAIC combined with sintilimab and bevacizumab for advanced hepatocellular carcinoma (HCC).
- Updated results from a Phase 2 study of HAIC plus sintilimab and bevacizumab biosimilar in patients with advanced HCC.
- A Phase 2 study of anlotinib combined with sintilimab versus chemotherapy combined with immunotherapy in perioperative NSCLC.
Ongoing Trials
Innovent will also present trial-in-progress (TiP) abstracts, including a Phase 3 study of IBI310 (anti-CTLA-4 antibody) plus sintilimab as neoadjuvant treatment for resectable microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colon cancer, and a study on the efficacy and safety of combination therapy of sintilimab and chemotherapy with cryoablation in the first-line treatment of advanced non-squamous non-small cell lung cancer (NSCLC).
"We are very pleased to present and share a robust set of clinical data at EAMO Asia 2024," said Dr. Hui Zhou, Senior Vice President of Innovent. "Notably, we are highlighting the breakthrough potential for our TOPO1i CLDN18.2 ADC (IBI343) in pancreatic cancer, a global difficult-to-treat cancer."
